AML
Item
unequivocal pathologic diagnosis of aml (>= 20% blasts in the bone marrow based on world health organization [who] criteria) excluding: acute promyelocytic leukemia t(15;17)(q22;q12); promyelocytic leukemia (pml)-retinoic acid receptor, alpha (rara) acute myeloid leukemia with t(8;21)(q22;q22); runt-related transcription factor 1 (runx1)-runt-related transcription factor 1; translocated to, 1 (runxt1) as determined by the ohio state university (osu) molecular reference laboratory, per cancer and leukemia group b (calgb) 20202; however patients who (1) are >= 75 years; and/or (2) have an ejection fraction of < 40%; and/or (3) have a performance status of > 2, may be registered to calgb 20202 and registered and treated on calgb 11002 prior to receiving the fms-related tyrosine kinase 3 (flt3) mutation and core-binding factor (cbf) molecular screening results from calgb 20202 acute myeloid leukemia with inv(16)(p13.1;q22) or t(16;16)(p13.1;q22); core-binding factor, beta subunit (cbfb)-myosin, heavy chain 11, smooth muscle (myh11) as determined by the osu molecular reference laboratory, per calgb 20202; however patients who (1) are >= 75 years; and/or (2) have an ejection fraction of < 40%; and/or (3) have a performance status of > 2, may be registered to calgb 20202 and registered and treated on calgb 11002 prior to receiving the flt3 mutation and cbf molecular screening results from calgb 20202
boolean
C0023467 (UMLS CUI [1])
C0023487 (UMLS CUI [2])
C1709412 (UMLS CUI [3])
C0001779 (UMLS CUI [4])
C0232174 (UMLS CUI [5])
C1518965 (UMLS CUI [6])
flt3 mutation
Item
absence of flt3 mutation (internal tandem duplication [itd] or point mutation) determined by the osu molecular reference laboratory, per calgb 20202; however patients who (1) are >= 75 years; and/or (2) have an ejection fraction of < 40%; and/or (3) have a performance status of > 2, may be registered to calgb 20202 and registered and treated on calgb 11002 prior to receiving the flt3 mutation and cbf molecular screening results from calgb 20202
boolean
C2348501 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
C0232174 (UMLS CUI [3])
C1518965 (UMLS CUI [4])
no prior treatment
Item
no prior treatment for aml except: emergency leukapheresis emergency treatment for hyperleukocytosis with hydroxyurea cranial radiotherapy (rt) for central nervous system (cns) leukostasis (one dose only) growth factor/cytokine support
boolean
C1514463 (UMLS CUI [1])
C0023416 (UMLS CUI [2,1])
C0013956 (UMLS CUI [2,2])
C0020402 (UMLS CUI [3,1])
C0013956 (UMLS CUI [3,2])
C1522449 (UMLS CUI [4,1])
C0282548 (UMLS CUI [4,2])
C0018284 (UMLS CUI [5])
C0199974 (UMLS CUI [6])
antecedent hematologic disorder (ahd) or myelodysplastic syndrome (mds)
Item
aml patients with an antecedent hematologic disorder (ahd) or myelodysplastic syndrome (mds) are eligible for this trial provided that they have not received treatment for their ahd or mds with cytotoxic chemotherapy (e.g., cytarabine, daunorubicin, etc.), decitabine, or bortezomib; patients may have been previously treated with azacitidine if their last dose was >= 90 days prior to starting 11002
boolean
C0018939 (UMLS CUI [1,1])
C0332152 (UMLS CUI [1,2])
C3463824 (UMLS CUI [2,1])
C0332152 (UMLS CUI [2,2])
C0392920 (UMLS CUI [3])
therapy-related myeloid neoplasms
Item
aml patients with therapy-related myeloid neoplasms (t-mn) are eligible if they have not received radiation therapy or chemotherapy (not including hormonal therapy) for their primary malignancy or disorder for > 6 months
boolean
C2939461 (UMLS CUI [1,1])
C0087111 (UMLS CUI [1,2])
C2924519 (UMLS CUI [1,3])
C1522449 (UMLS CUI [2])
C0392920 (UMLS CUI [3])